User menu

Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study

Bibliographic reference Genovese, Mark C ; Fleischmann, Roy ; Furst, Daniel ; Janssen, Namieta ; Carter, John ; et. al. Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study. In: Annals of the Rheumatic Diseases, Vol. 73, no. 9, p. 1607-1615 (2014)
Permanent URL http://hdl.handle.net/2078.1/156549
  1. De Bruyn, Arthritis Rheum, 64, S561 (2012)
  2. Finch Donna K., Sleeman Matthew A., Moisan Jacques, Ferraro Franco, Botterell Sara, Campbell Jamie, Cochrane Duncan, Cruwys Simon, England Elizabeth, Lane Steven, Rendall Elizabeth, Sinha Monisha, Walker Craig, Rees Gareth, Bowen Michael A., Schneider Amy, Liang Meina, Faggioni Raffaella, Fung Michael, Mallinder Philip R., Wilkinson Trevor, Kolbeck Roland, Vaughan Tristan, Lowe David C., Whole-Molecule Antibody Engineering: Generation of a High-Affinity Anti-IL-6 Antibody with Extended Pharmacokinetics, 10.1016/j.jmb.2011.06.031
  3. Genovese MC, Kivitz AJ, Simon Campos JA . Sarilumab for the Treatment of Moderate-to-Severe Rheumatoid Arthritis: Results of a Phase 2, Randomized, Double-Blind, Placebo-Controlled, International Study. ACR/ARHP Annual Scientific Meeting; Chicago. 2011.
  4. Hsu B., Sheng S., Weinblatt M.E., Smolen J.S., OP0025 Results from a multicenter, international, randomized, double-blind, placebo-controlled, phase 2 study of sirukumab, a human anti-IL-6 monoclonal antibody, in patients with active rheumatoid arthritis despite methotrexate therapy, 10.1136/annrheumdis-2012-eular.1708
  5. Mease P, Strand V, Shalamberidze L, Dimic A, Raskina T, Xu Li-An, Liu Y, Smith J, A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate, 10.1136/annrheumdis-2011-200704
  6. Gabay Cem, Emery Paul, van Vollenhoven Ronald, Dikranian Ara, Alten Rieke, Pavelka Karel, Klearman Micki, Musselman David, Agarwal Sunil, Green Jennifer, Kavanaugh Arthur, Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial, 10.1016/s0140-6736(13)60250-0
  7. Maini R. N., Taylor P. C., Szechinski J., Pavelka K., Bröll J., Balint G., Emery P., Raemen F., Petersen J., Smolen J., Thomson D., Kishimoto T., , Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate, 10.1002/art.22033
  8. Tatarewicz Suzanna, Miller Jill M., Swanson Steven J., Moxness Michael S., Rheumatoid factor interference in immunogenicity assays for human monoclonal antibody therapeutics, 10.1016/j.jim.2010.03.012
  9. Araujo James, Zocher Marcel, Wallace Kristin, Peng Kun, Fischer Saloumeh Kadkhodayan, Increased rheumatoid factor interference observed during immunogenicity assessment of an Fc-engineered therapeutic antibody, 10.1016/j.jpba.2011.03.008
  10. STEINBROCKER OTTO, THERAPEUTIC CRITERIA IN RHEUMATOID ARTHRITIS, 10.1001/jama.1949.02900430001001
  11. Aletaha Daniel, Neogi Tuhina, Silman Alan J., Funovits Julia, Felson David T., Bingham Clifton O., Birnbaum Neal S., Burmester Gerd R., Bykerk Vivian P., Cohen Marc D., Combe Bernard, Costenbader Karen H., Dougados Maxime, Emery Paul, Ferraccioli Gianfranco, Hazes Johanna M. W., Hobbs Kathryn, Huizinga Tom W. J., Kavanaugh Arthur, Kay Jonathan, Kvien Tore K., Laing Timothy, Mease Philip, Ménard Henri A., Moreland Larry W., Naden Raymond L., Pincus Theodore, Smolen Josef S., Stanislawska-Biernat Ewa, Symmons Deborah, Tak Paul P., Upchurch Katherine S., Vencovský Jiří, Wolfe Frederick, Hawker Gillian, 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative, 10.1002/art.27584
  12. Arnett Frank C., Edworthy Steven M., Bloch Daniel A., Mcshane Dennis J., Fries James F., Cooper Norman S., Healey Louis A., Kaplan Stephen R., Liang Matthew H., Luthra Harvinder S., Medsger Thomas A., Mitchell Donald M., Neustadt David H., Pinals Robert S., Schaller Jane G., Sharp John T., Wilder Ronald L., Hunder Gene G., The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis, 10.1002/art.1780310302
  13. Roche. RoACTEMRA (tocilizumab) Summary of Product Characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000955/WC500054890.pdf (accessed 8 Aug 2013).
  14. Fleischmann, Ann Rheum Dis, 70, 471 (2011)
  15. Hickling, Ann Rheum Dis, 70, 471 (2011)
  16. Genentech Inc. ACTEMRA (tocilizumab) Full Prescribing Information. Revised: 04/2013. http://www.actemra.com/ (accessed 10 Dec 2013).
  17. Nishimoto Norihiro, Miyasaka Nobuyuki, Yamamoto Kazuhiko, Kawai Shinichi, Takeuchi Tsutomu, Azuma Junichi, Kishimoto Tadamitsu, Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy, 10.3109/s10165-008-0125-1
  18. Nishimoto N., Hashimoto J., Miyasaka N., Yamamoto K., Kawai S., Takeuchi T., Murata N., van der Heijde D., Kishimoto T., Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab, 10.1136/ard.2006.068064
  19. Nakashima Yasuharu, Kondo Masakazu, Harada Hiroshi, Horiuchi Takahiko, Ishinishi Takashi, Jojima Hiroshi, Kuroda Koji, Miyahara Hisaaki, Nagamine Ryuji, Nakashima Hitoshi, Otsuka Takeshi, Saikawa Isao, Shono Eisuke, Suematsu Eiichi, Tsuru Tomomi, Wada Ken, Iwamoto Yukihide, Clinical evaluation of tocilizumab for patients with active rheumatoid arthritis refractory to anti-TNF biologics: tocilizumab in combination with methotrexate, 10.3109/s10165-010-0290-x
  20. Hushaw, Ther Clin Risk Manag, 6, 143 (2010)
  21. Hashimoto Jun, Garnero Patrick, van der Heijde Désirée, Miyasaka Nobuyuki, Yamamoto Kazuhiko, Kawai Shinichi, Takeuchi Tsutomu, Yoshikawa Hideki, Nishimoto Norihiro, Humanized anti-interleukin-6-receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomarkers, radiography, and BMI: data from the SAMURAI study, 10.3109/s10165-010-0325-3
  22. Genovese Mark C., McKay James D., Nasonov Evgeny L., Mysler Eduardo F., da Silva Nilzio A., Alecock Emma, Woodworth Thasia, Gomez-Reino Juan J., Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study, 10.1002/art.23940
  23. Emery P., Keystone E., Tony H. P., Cantagrel A., van Vollenhoven R., Sanchez A., Alecock E., Lee J., Kremer J., IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial, 10.1136/ard.2008.092932
  24. Dougados Maxime, Kissel Karsten, Sheeran Tom, Tak Paul P, Conaghan Philip G, Mola Emilio Martín, Schett Georg, Amital Howard, Navarro-Sarabia Federico, Hou Antony, Bernasconi Corrado, Huizinga TWJ, Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY), 10.1136/annrheumdis-2011-201282
  25. Srirangan Srinivasan, Choy Ernest H., The role of Interleukin 6 in the pathophysiology of rheumatoid arthritis, 10.1177/1759720x10378372
  26. Sack U., Kinne R. W., Marx T., Heppt P., Bender S., Emmrich F., Interleukin-6 in synovial fluid is closely associated with chronic synovitis in rheumatoid arthritis, 10.1007/bf00307733
  27. Kokebie Rediet, Aggarwal Rohit, Lidder Sukhwinderjit, Hakimiyan Arnavaz A, Rueger David C, Block Joel A, Chubinskaya Susan, The role of synovial fluid markers of catabolism and anabolism in osteoarthritis, rheumatoid arthritis and asymptomatic organ donors, 10.1186/ar3293
  28. McInnes Iain B., Schett Georg, Cytokines in the pathogenesis of rheumatoid arthritis, 10.1038/nri2094
  29. Rubbert-Roth Andrea, Finckh Axel, Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review, 10.1186/ar2666
  30. Marchesoni Antonio, Zaccara Eleonora, Gorla Roberto, Bazzani Chiara, Sarzi-Puttini Piercarlo, Atzeni Fabiola, Caporali Roberto, Bobbio-Pallavicini Francesca, Favalli Ennio Giulio, TNF-α Antagonist Survival Rate in a Cohort of Rheumatoid Arthritis Patients Observed under Conditions of Standard Clinical Practice, 10.1111/j.1749-6632.2009.04621.x
  31. Cohen, J Rheumatol Suppl, 81, 4 (2008)
  32. Smolen J. S., Landewe R., Breedveld F. C., Dougados M., Emery P., Gaujoux-Viala C., Gorter S., Knevel R., Nam J., Schoels M., Aletaha D., Buch M., Gossec L., Huizinga T., Bijlsma J. W. J. W., Burmester G., Combe B., Cutolo M., Gabay C., Gomez-Reino J., Kouloumas M., Kvien T. K., Martin-Mola E., McInnes I., Pavelka K., van Riel P., Scholte M., Scott D. L., Sokka T., Valesini G., van Vollenhoven R., Winthrop K. L., Wong J., Zink A., van der Heijde D., EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs, 10.1136/ard.2009.126532
  33. Jacobsson L. T H, Turesson C., Nilsson J.-A., Petersson I. F, Lindqvist E., Saxne T., Geborek P., Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis, 10.1136/ard.2006.062497